Global medical device company St. Jude Medical (NYSE:STJ) announced international launch of its MediGuide navigation technology, which turns pre-recorded fluoroscopic images into 3-D visualizations that physicians can use to direct cardiovascular procedures in real time.
The company likens MediGuide to a sort of cardiovascular GPS system, providing precise location and orientation information about enabled devices inside the heart during procedures.
“The launch of MediGuide Technology is significant as it allows clinicians to perform cardiac procedures with less fluoroscopy and the corresponding exposure to harmful radiation,” Dr. Dhanunjaya Lakkireddy said, in prepared remarks, on behalf of the company. “This revolutionary system reduces the need for live fluoroscopy, while providing unprecedented views inside the heart, improving complex cardiac resynchronization therapy and cardiac ablation image-guided procedures for physicians, patients and medical staff around the world.”
Lakkireddy is a cardiologist at the University of Kansas Hospital, the 1st medical facility in the U.S. to use the MediGuide system.
"St. Jude Medical will continue developing technologies that minimize radiation exposure in the EP lab, improve procedural repeatability and increase clinical and economic efficiency," St. Jude Medical cardiovascular and ablation technologies division president Frank Callaghan said in a company statement.
STJ shares lost 2.3% today, closing at $42.32.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.